Boston Scientific Corp. offers the PROMUS Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease. The PROMUS Stent is a private-labeled XIENCE V Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific under an agreement executed prior to the 2006 acquisition of the former Guidant Corp. by Boston Scientific.

July 3, 2008 - Boston Scientific Corp. today said the FDA has approved the PROMUS Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease.

The PROMUS Stent is a private-labeled XIENCE V Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific under an agreement executed prior to the 2006 acquisition of the former Guidant Corp. by Boston Scientific. FDA approval clears the way for Boston Scientific to launch the PROMUS Stent immediately in the U.S.

July 2, 2008 - The Society for Cardiovascular Angiography and Interventions (SCAI), the leading professional organization for interventional cardiology, has expanded its educational Web site (www.seconds-count.org) with a new section dedicated to health professionals who work with interventional cardiologists and care for patients with cardiovascular disease.

July 2, 2008 - The European Alliance for Access to Safe Medicines (EAASM) has today unveiled its comprehensive research report, “The Counterfeiting Superhighway,” which reveals that a frightening 62 percent of medicines purchased online are fake or substandard.

July 1, 2008 - The impact of surgeons' annual aortic volume and other prognostic indicators have been revealed in early outcomes of ruptured abdominal aortic aneurysm (RAAA) repair in a recent study from the University of Pittsburgh Medical Center.

Details of the study have been published in the July issue of the Journal of Vascular Surgery.

July 1, 2008 - The FDA is asking healthcare professionals and facilities check all drug and device storage areas, including emergency kits, crash carts and automated drug storage cabinets to make sure all recalled heparin products have been removed and are no longer available for use.

"The investigation of contaminated heparin is still underway. Over the past several months, FDA has been alerting healthcare professionals and the public about medical products that may contain contaminated heparin, which has been associated with a number of serious adverse events.

July 1, 2008 - An interventional cardiology team this week led by Professor Patrick W. Serruys, M.D., Ph.D, successfully placed a vProtect Luminal Shield in the left anterior descending (LAD) coronary artery of a 64-year-old man at Erasmus Medical Center in Rotterdam.

July 1, 2008 - CryoCath Technologies introduced the Arctic Front in Italy, Belgium and Spain, aiming to provide better treatment of paroxysmal atrial fibrillation (PAF) with its cryoablation balloon catheter that allows physicians to isolate all four pulmonary veins.

July 1, 2008 - American TeleCare Inc. (ATI) said today NuPhysicia LLC adopted ATI's CareTone Ultra digital stethoscope into the B3Zero Telemedicine Suitcase System.

July 1, 2008 - Toshiba Medical Systems Corp. (TMSC), the parent company of Toshiba America Medical Systems Inc., appointed Kenichi Komatsu, M.D., president and CEO.

He will replace Masamichi Katsurada, who will now serve as an adviser to the board of TMSC and the Toshiba Corp.

A graduate of Hokkaido University in Japan, Dr. Komatsu joined the Toshiba in 1978 and most recently served as executive vice president, Toshiba Medical Systems Corp.

For more information: www.medical.toshiba.com

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now